<div id="readability-page-1" class="page">Pfizer's cancer push: Pfizer will pay Innovent $650M upfront in a deal worth up to $10.5B, aiming to co-develop 12 oncology programs and expand its cancer drug pipeline. Lilly's vaccine spree: Eli Lilly will acquire Curevo, LimmaTech, and Vaccine Co. for up to $4B combined, bolstering its position in infectious disease prevention. Global market impact: These transactions signal heightened cross-border collaboration and competition in biopharma, potentially accelerating access to new treatments worldwide.</div>

01801

<p>Pfizer agreed to a deal worth up to $10.5B with Innovent, paying $650M upfront to co-develop 12 oncology programs. Simultaneously, Eli Lilly is acquiring Curevo, LimmaTech, and Vaccine Co. for up to $4B combined to strengthen its vaccine portfolio. These major transactions highlight intensified cross-border collaboration and competition in the biopharma sector, potentially accelerating global access to new treatments.</p>

- Pfizer has agreed to pay Innovent $650 million upfront in a deal potentially worth up to $10.5 billion to co-develop 12 oncology programs.  
- Eli Lilly plans to acquire Curevo, LimmaTech, and Vaccine Co. for up to $4 billion to strengthen its presence in infectious disease prevention.  
- These transactions reflect increased collaboration and competition in the biopharma sector, which may enhance global access to new treatments.

Pfizer

Eli Lilly

INNOVENT BIO

iShares Biotechnology ETF

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

VG Health

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Direxion Daily LLY Bear 1X Shares

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bear 3X

iShares Global Healthcare

Defiance Daily Target 2X Short LLY ETF

Pfizer inks $10.5B oncology deal as Lilly expands vaccines